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Abstract
Background: Mycobacterium avium subspecies paratuberculosis (MAP) may be zoonotic. Recently the ‘‘immuno-modulators’’
methotrexate, azathioprine and 6-MP and the ‘‘anti-inflammatory’’ 5-ASA have been shown to inhibit MAP growth in vitro. We
concluded that their most plausible mechanism of action is as antiMAP antibiotics. The ‘‘immunosuppressants’’ Cyclosporine
A, Rapamycin and Tacrolimus (FK 506) treat a variety of ‘‘autoimmune’’ and ‘‘inflammatory’’ diseases. Rapamycin and
Tacrolimus are macrolides. We hypothesized that their mode of action may simply be to inhibit MAP growth.
Methodology: The effect on radiometric MAP
14CO2 growth kinetics of Cyclosporine A, Rapamycin and Tacrolimus on MAP
cultured from humans (Dominic & UCF 4) or ruminants (ATCC 19698 & 303) and M. avium subspecies avium (ATCC 25291 &
101) are presented as ‘‘percent decrease in cumulative GI’’ (%-DcGI.)
Principal Findings: The positive control clofazimine has 99%-DcGI at 0.5 mg/ml (Dominic). Phthalimide, a negative control
has no dose dependent inhibition on any strain. Against MAP there is dose dependent inhibition by the
immunosuppressants. Cyclosporine has 97%-DcGI by 32 mg/ml (Dominic), Rapamycin has 74%-DcGI by 64 mg/ml (UCF 4)
and Tacrolimus 43%-DcGI by 64 mg/ml (UCF 4)
Conclusions: We show heretofore-undescribed inhibition of MAP growth in vitro by ‘‘immunosuppressants;’’ the cyclic
undecapeptide Cyclosporine A, and the macrolides Rapamycin and Tacrolimus. These data are compatible with our thesis
that, unknowingly, the medical profession has been treating MAP infections since 1942 when 5-ASA and subsequently
azathioprine, 6-MP and methotrexate were introduced in the therapy of some ‘‘autoimmune’’ and ‘‘inflammatory’’ diseases.
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Introduction
The ‘‘immunosuppressants’’ Cyclosporine A [1], Rapamycin
[2] and Tacrolimus (FK 506) [3] have conventionally been used to
prevent or treat the rejection of transplanted organs.[4–8] They
have well described mechanisms of actions [9,10] including
calcineurin phosphatase inhibition by Cyclosporine and Tacroli-
mus and cell cycle inhibition by Rapamycin.[11] These agents are
also used in the therapy of a variety of ‘‘autoimmune’’ and
‘‘inflammatory’’ diseases including inflammatory bowl disease
(IBD) [12–19], skin diseases [20], asthma [21] and rheumatoid
arthritis.[22,23] Generally, the effect of these immunosuppressants
has been studied on intact animals or eukaryotic cells, although the
effect on viruses has been addressed.[24]
M. avium subspecies paratuberculosis (MAP) causes a chronic
wasting enteritis in ruminants called Johne’s disease [25] that is
highly evocative of Crohn’s disease (CD.) [26] MAP has been
cultured from USA chlorinated potable municipal water [27],
pasteurized milk in the USA [28], and Europe [29] [30], breast
milk of mothers with CD [31] and from the blood of patients with
IBD. [32] Although controversial, there are increasingly compel-
ling data [27,32–35] (& see [36] for review) that Mycobacterium
avium subspecies paratuberculosis (MAP) may be zoonotic. [33]
Until recently, it was unrecognized that the ‘‘anti-inflammato-
ry’’ 5 amino salicylic acid (5-ASA) [37] and the ‘‘immune
modulators’’ methotrexate [34], azathioprine [38] and its
metabolite 6-mercapto-purine (6-MP) [34], [38] are antiMAP
antibiotics. Antecedent studies evaluating the potential zoonotic
character of MAP had permitted these ‘‘anti-inflammatory’’ and
‘‘immune-modulating’’ agents to be used in the control groups, as
their antiMAP activity was not appreciated. We therefore
concluded that all those prior studies now need to be reevaluated,
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prevailing medical dogma [39] considers that MAP is not
zoonotic.
It is of considerable interest that all three ‘‘immunosuppres-
sants’’ were isolated from fungi, the source of multiple
antibacterial antibiotics. Cyclosporine A, a cyclic undecapeptide,
has immunosuppressant, anti-rheumatic [40,41], dermatological
[42] and anti-asthmatic [21] activity. Tacrolimus [3,20] and
Rapamycin [2,20] are from the macrolide antibiotic family of
medications, amongst the most potent anti M. avium antibiotic
families. [43]
We hypothesized that in addition to their protean effects on
eukaryotes [9–11,44–46], and fungi [47], Cyclosporine A,
Rapamycin and Tacrolimus, may also effect prokaryotes.
Specifically we hypothesized that they would have antiMAP
antibiotic activity. Accordingly, in bacterial culture we evaluate the
effect of Cyclosporine A, Rapamycin and Tacrolimus on M. avium,
including its subspecies MAP.
Methods
This study was approved by the Research & Development
Committee at the VAMC Bronx NY (0720-06-038) and was
conducted under the Institutional Radioactive Materials Permit
(#31-00636-07).
Figure 1. Shown are the inhibition data for a study employing
MAP Dominic. The agents evaluated are Cyclosporine, Rapamycin and
Tacrolimus. Of these three agents, the most pronounced inhibition is
observed with Cyclosporine (see also Table 4.) Error bars are 6SD.
cGI=cumulative Growth Index (BactecH) The GI was 240 at the time of
passage.
doi:10.1371/journal.pone.0002496.g001
Figure 2. Shown is a composite of four MAP strains. The upper two are MAP isolated from humans, the lower two, MAP isolated from
ruminants. ‘‘UMW 303’’ is University of Madison Wisconsin. UCF -4 is University of Central Florida. Note how cyclosporine is consistently the most
effective of the three ‘‘immunosuppressants’’ tested (see also Table 5) followed by Rapamycin. The least effective of the three macrolides is
Tacrolimus. cGI=cumulative Growth Index (BactecH) For Dominic the GI was 331 at the time of passage.
doi:10.1371/journal.pone.0002496.g002
Immunosuppressants & MAP
PLoS ONE | www.plosone.org 2 June 2008 | Volume 3 | Issue 6 | e2496Bacterial Culture
In this study we studied six strains of mycobacteria, four of
which were MAP. Two MAP strains had been isolated from
humans with Crohn’s disease. Dominic (ATCC 43545, originally
isolated by R. Chiodini from the intestine of a patient with
Crohn’s disease [48]) and UCF 4 (gift of Saleh Naser UCF
Orlando FL., originally cultured from the blood of a patient with
Crohn’s disease.)[32] The other two MAP strains were from
ruminants with Johne’s disease ATCC 19698 (ATCC Rockville
MD) and 303 (gift of Michael Collins Madison WI.) The M. avium
subspecies avium strains (hereinafter called M. avium) were ATCC
25291 (veterinary source) and M. avium 101. [49]
Because it renders clinically resistant strains of MAP inappro-
priately susceptible to antimicrobials in cell culture, [50] we did
not use the detergent Tween 80 (recommended to prevent
mycobacterial clumping) in culture. Prior to inoculation, cultures
were processed as described. [34,37,51]
In this study, for experimental comparability we used chemicals
that could be solubilized with DMSO (Sigma St Louis MO.) The
positive control antibiotic was clofazimine (an antibiotic used to
treat leprosy [52] and now in clinical trials against Crohn’s disease
[39,53].) The two negative controls are the gluterimide antibiotics,
cycloheximide and phthalimide.
The tested agents Cyclosporine A, Rapamycin and Tacrolimus
(Sigma & LC Labs. Woburn MA) were solubilized in 100%
DMSO. Aliquots were prediluted, stored at 280uC in 50%
DMSO (Sigma) & 50% water, thawed, used once and discarded.
Volumes of DMSO were adjusted so that final concentration in
every Bactec vial used was always 3.2% DMSO. Agents were
tested in serial dilutions from a minimum of 0.5 mg/ml to a
maximum of 64 mg/ml (see individual Figures & Tables).
Inhibition of mycobacterial growth is expressed as % -DcGI,
and enhancement as % +DcGI compared to 3.2% DMSO
controls. [37]
Data are presented in two ways: For individual mycobacterial
strains as graphs (MAP in Figures 1& 2, and M. avium in Figure 3.)
For individual chemical agents data are presented in tabular form.
The positive experimental control is clofazimine (Table 1.) The
‘‘negative’’ controls are cycloheximide (Table 2) and phthalimide
(Table 3.) Data for the ‘‘immunosuppressives’’ are Cyclosporine A
(Table 4), Rapamycin (Table 5) and Tacrolimus (Table 6.)
In Table 7 we present the ‘‘High’’ trough doses of the three
immunosuppressives that are used to treat organ transplant
rejection in eukaryotes. These are compared with the ‘‘Low’’
dose that are used to treat ‘‘inflammatory’’ diseases and that we
posit are actually treating a prokaryote (specifically we suggest a
MAP) infection.
Results
The most potent positive control is clofazimine, 97% 2DcGI at
0.5 (Dominic; Figure 1 & Table 1.) The negative controls chemical
agents are the gluterimide antibiotics cycloheximide and phtha-
limide. Cycloheximide has no dose dependent inhibition on any
MAP strain (Figures 1 & 2 & Table 2.) Cycloheximide has dose
dependent inhibition on M. avium ATCC 25291, (57% 2DcGI at
64 mg/ml) but no effect on M. avium 101 (Figure 3 & Table 2.)
Phthalimide, has no dose dependent effect on any strain tested
(Figures 1–3 and Table 3.)
The three ‘‘Immunosuppressants’’ tested were Cyclosporine A,
Rapamycin and Tacrolimus. There are differing amounts of
inhibition depending on the agent and strain.
The control mycobacterial strains are M. avium subspecies avium
ATCC 25291 and 101. Of the three ‘‘Immunosuppressants,’’
Cyclosporine A has dose dependent inhibition on M. avium
subspecies avium 101 (95% 2DcGI at 64 mg/ml) (Figure 3 and
Table 4.) There is no inhibition with Rapamycin or Tacrolimus on
the control M. avium 25291 (Figure 3 and Table 5 & 6.)
Against MAP, Cyclosporine A is the most effective of the three
‘‘immunosuppressants’’ studied. On MAP isolated from humans,
(Dominic and UCF 4), Cyclosporine has 97% 2DcGI at 32 mg/ml
against Dominic (Figure 1) and 99% 2DcGI at 64 mg/ml on
Dominic and UCF 4 (Figure 2 & Table 4.) On MAP isolated from
ruminants, Cyclosporine A has slightly less dose dependent
Figure 3. Shown is a composite of two M. avium subspecies
avium strains ATCC 25291 & 101. Tacrolimus has most inhibition on
M. avium 101 but enhances growth on M. avium ATCC 25291
cGI=cumulative Growth Index (BactecH).
doi:10.1371/journal.pone.0002496.g003
Table 1. %-DcGI Clofazimine.
mg/ml Mycobacterial strain
M. avium subspecies paratuberculosis
(MAP) M. avium
Human MAP Bovine MAP Bovine
Dominic UCF 4 303 19698 25291 101
Fig. 1 Fig. 2 Fig. 2 Fig. 2 Fig. 2 Fig. 3 Fig. 3
1 299% 299% 299% 299% 299% 298% 298%
4 299% 299% 299% 299% 299% 298% 298%
16 299% 299% 299% 299% 299% 298% 298%
64 299% 299% 299% 299% 299% 299% 299%
%-DcGI=percent decrease in cumulative GI compared to control inoculation.
doi:10.1371/journal.pone.0002496.t001
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MAP isolated from humans (Figure 2 & Table 4.)
Rapamycin is the second most effective ‘‘immunosuppressant’’
studied. At lower concentrations (1 & 16 mg/ml) Rapamycin has
no inhibition and by 64 mg it has 76% 2DcGI on UCF 4, a MAP
isolated from humans (Figure 2 & Table 5). Rapamycin is less
effective against MAP isolated from ruminants and has no effect
on M. avium ATCC 25291 (Figure 3 & Table 5.)
Table 2. %-DcGI Cycloheximide.
mg/ml Mycobacterial strain
M. avium subspecies paratuberculosis
(MAP) M. avium
Human MAP Bovine MAP Bovine
Dominic UCF 4 303 19698 25291 101
Fig. 1 Fig. 2 Fig. 2 Fig. 2 Fig. 2 Fig. 3 Fig. 3
1 15% 9% 1% 3% 22% 0% 6%
4 24% 0% 27% 4% 27% 28% 7%
16 28% 24% 24% 25% 212% 27% 1%
64 21% 27% 212% 24% 29% 257% 5%
%-DcGI=percent decrease in cumulative GI compared to control inoculation.
doi:10.1371/journal.pone.0002496.t002
Table 3. %-DcGI Phthalimide.
mg/ml Mycobacterial strain
M. avium subspecies paratuberculosis
(MAP) M. avium
Human MAP Bovine MAP Bovine
Dominic UCF 4 303 19698 25291 101
Fig. 1 Fig. 2 Fig. 2 Fig. 2 Fig. 2 Fig. 3 Fig. 3
1 23% 21% 4% 22% 22% 2% 23%
47 % 0 % 22% 3% 210% 4% 4%
16 0% 1% 1% 213% 1% 1% 2%
64 2% 4% 3% 6% 0% 12% 22%
%-DcGI=percent decrease in cumulative GI compared to control inoculation.
doi:10.1371/journal.pone.0002496.t003
Table 4. %-DcGI Cyclosporine A.
mg/ml Mycobacterial strain
M. avium subspecies paratuberculosis
(MAP) M. avium
Human MAP Bovine MAP Bovine
Dominic UCF 4 303 19698 25291 101
Fig. 1 Fig. 2 Fig. 2 Fig. 2 Fig. 2 Fig. 3 Fig. 3
11 5 % 4 % 22% 21% 22% 22% 228%
4 210% 29% 5% 23% 223% 31% 244%
16 243% 264% 29% 214% 219% 4% 256%
64 298% 299% 299% 291% 292% 254% 295%
%-DcGI=percent decrease in cumulative GI compared to control inoculation.
doi:10.1371/journal.pone.0002496.t004
Table 5. %-DcGI Rapamycin.
mg/ml Mycobacterial strain
M. avium subspecies paratuberculosis
(MAP) M. avium
Human MAP Bovine MAP Bovine
Dominic UCF 4 303 19698 25291 101
Fig. 1 Fig. 2 Fig. 2 Fig. 2 Fig. 2 Fig. 3 Fig. 3
1 21% 0% 214% 4% 23% 10% 219%
41 3 % 27% 29% 211% 21% 7% 27%
16 210% 29% 229% 215% 218% 11% 228%
64 258% 244% 276% 239% 243% 218% 239%
%-DcGI=percent decrease in cumulative GI compared to control inoculation.
doi:10.1371/journal.pone.0002496.t005
Table 6. %-DcGI Tacrolimus.
mg/ml Mycobacterial strain
M. avium subspecies paratuberculosis
(MAP) M. avium
Human MAP Bovine MAP Bovine
Dominic UCF 4 303 19698 25291 101
Fig. 1 Fig. 2 Fig. 2 Fig. 2 Fig. 2 Fig. 3 Fig. 3
1 28% 5% 6% 5% 8% 223% 234%
49 % 9 % 219% 3% 23% 23% 243%
16 21% 210% 218% 25% 25% 11% 240%
64 0% 221% 243% 227% 226% 53% 252%
%-DcGI=percent decrease in cumulative GI compared to control inoculation.
doi:10.1371/journal.pone.0002496.t006
Table 7. Immunosuppressant Therapeutic Trough levels used
in ‘‘High’’ dose for transplantation rejection and ‘‘Low’’ dose in
‘‘Inflammatory’’ Diseases.
Medication Targeted Trough levels (ng/ml)
‘‘High’’ level for
Organ Transplant
Rejection
‘‘Low’’ level in
‘‘Inflammatory’’
Diseases
ng/ml Citation ng/ml Citation
Cyclosporine A 100–400 [63] 70–130 [14]
396 [64] 100–200 [12]
350–400 [65]
Tacrolimus (FK 506) 5–20 [63] 4–8 [67]
17–18 [66] 5–10 [68]
Rapamycin 5–15 [63] No data available
(PubMed)
doi:10.1371/journal.pone.0002496.t007
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pressants’’ studied. Against MAP, Tacrolimus is most inhibitory
against UCF 4 (43% 2DcGI at 64 mg/ml) and ATCC 19698:
26% 2DcGI at 64 mg/ml) (Figures 1 & 2 and Table 6.)
Paradoxically, Tacrolimus exhibits the most inhibition on M.
avium 101 of all six strains studied, yet actually enhances growth on
M. avium ATCC 25291. (Figure 3 and Table 6.)
Discussion
Rapamycin was initially evaluated as an anti-fungal agent. [54]
To our knowledge however, this is the first time that antiMAP
activity has been demonstrated for the ‘‘immunosuppressant’’
agents Cyclosporine, Rapamycin and Tacrolimus. These obser-
vations are therefore compatible with our thesis that MAP may be
responsible for multiple ‘‘autoimmune’’ and ‘‘inflammatory’’
diseases, and that the action of these three ‘‘immunosuppressant’’
agents may simply be to inhibit MAP growth.
We have observed that methotrexate and 6-MP are used in
‘‘high’’ doses to treat human malignancies and at ‘‘low’’ doses in
‘‘autoimmune’’ and ‘‘inflammatory’’ conditions. [34] Similarly,
there are ‘‘high’’ and ‘‘low’’ doses of the three ‘‘immunosuppres-
sants’’ we now study (See Table 7.) The ‘‘high’’ doses are used to
prevent or treat transplanted organ rejection. The ‘‘low’’ doses are
used to treat ‘‘autoimmune’’ and ‘‘inflammatory’’ diseases. These
data are compatible with our hypothesis that Cyclosporine, a
cyclic undecapeptide, as well as Rapamycin and Tacrolimus, from
the macrolide family of antibiotics, may have ‘‘low’’ dose
prokaryotic antibiotic action in addition to ‘‘high’’ dose eukaryotic
immunosuppressant activity.
Our observations are subtle and the negative controls are
critical. For those not conversant with quantifying mycobacterial
growth and determining the inhibitory effect of various agents, it
must be emphasized that these data were obtained using the
exquisitely sensitive radiometric
14C Bactec systemH. Just as with
5-ASA [37,38], these effects may not be detectable using the more
convenient, fluorescent based MIGT systemH.
The chronic use of antibiotics, even for complex mycobacterial
diseases, is not advocated. With leprosy the WHO recommends
that MDT be limited to #2 years [52] and for tuberculosis #18
months and preferably six months. [55] The ‘‘immunosuppres-
sant, ’’ ‘‘antiinflammatory’’ and ‘‘immunomodulatory’’ agents that
we show are antiMAP antibiotics have been administered
indefinitely.
In the event that MAP is accepted as being zoonotic, there will
need to be a reevaluation of how best to manage MAP infections
in humans. There will be multiple factors that will then need to be
taken into consideration. These include the fact that successfully
treated leprosy and tuberculosis infections do not lead to
mycobacterial eradication. Often the bacteria merely enter into
a quiescent or ‘‘latent’’ phase and clinical symptoms progress [56]
despite apparently ‘‘adequate’’ therapy. It will also be necessary to
prevent reinfection, by removing MAP from the water supply [27],
and food chain.[28] Genetic defects [57–59] that predispose to
MAP infections will need to be identified, as affected individuals
may need life long antiMAP therapy. Optimal MAP antibiotic
combinations will need to be established. Designing clinical trial
that consider the recently described antiMAP activity of ‘‘antiin-
flammatories’’, ‘‘immunomodulators’’ and ‘‘immunosuppressants’’
will need to be performed. Finally, the role of MAP pre and post
exposure vaccination will need to be addressed. [60–62]
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